Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                International Activities

International Activities

                        Regulatory Harmonization and Convergence
          Foreign Regulators – Information and Training Resources
          Foreign Regulator Information Exchanges
          International Engagements to Respond to Covid-19 Pandemic
          Quick Guide to Web Resources
          Foreign Regulatory Seminar (Web-Based): CBERs Regulation of Biologics


                        WHO Engagements Home
          Vaccines, Blood & Biologics
          International Activities
          Foreign Regulator Information ExchangesInternational Activities Foreign Regulator Information Exchanges
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe U.S. Food and Drug Administration’s (FDA) mission, as amended in the Food and Drug Administration Modernization Act of 1997, includes the mandate to, “participate through appropriate processes with representatives of other countries to reduce the burden of regulation, harmonize regulatory requirements, and achieve appropriate reciprocal arrangements.”  In support of this mission element, the FDA’s Center for Biologics Evaluation and Research (CBER) exchanges critical regulatory information on an on-going basis with foreign regulatory counterparts using a range of mechanisms.  CBER undertakes information exchanges with counterparts in the Americas, Europe, Africa, Asia and Australia, as well as with international organizations such as the World Health Organization and the Pan American Health Organization. These information exchanges enhance CBER’s ability to meet its responsibilities of ensuring the safety and effectiveness of the products it regulates, and earning the public’s trust. CBER accomplishes this by expanding the pool of expertise and information sources from which it can draw in order to produce comprehensive, informed decisions.

CBER undertakes a number of structured scientific and policy discussions under confidentiality commitments with foreign regulatory counterparts. Some of the most vital regulatory discussions that occur throughout the year are known as “Clusters.” These Clusters are established, routine discussions around specific subject matter areas that involve experts from CBER, other FDA components as appropriate, the European Medicines Agency (EMA), the Health Products and Food Branch (HPFB) of Health Canada (HC), Government of Japan’s Ministry of Health, Labour and Welfare, and Pharmaceuticals and Medical Devices Agency, and the Therapeutic Goods Administration of Australia.  CBER is a principal participant in the Clusters for Blood Products, Advanced Therapy Medicinal Products, and Vaccines; it additionally participates as appropriate in the Agency Oncology, Pediatric, Pharmacovigilance, Biosimilar and Pharmacogenomic Clusters.

CBER’s information exchanges may consist of publicly available information, or may be of a non-public nature when conducted under the Agency’s Confidentiality Commitments, Memoranda of Understanding and other Cooperative Arrangements.  CBER both initiates and responds to *ad hoc* requests for information exchanges with foreign regulatory counterparts on a range of issues, including:

product manufacturing issues
	potential product shortages
	inspectional issues
	data interpretation
	post-marketing surveillance signals
	preapproval considerationsCBER also undertakes Parallel Scientific Advice (PSA) with the EMA.  The PSA process is one in which a sponsor seeks joint scientific advice from FDA and EMA on issues related to the development phase of a new product.  The benefits of these interactions include the following:

an increased dialogue between the two agencies and sponsors at various points of the lifecycle of a new product
	a deeper understanding of the bases of scientific advice, and an opportunity to optimize product development
	the avoidance of unnecessary testing replication or unnecessary diverse testing methodologiesIn addition, CBER frequently hosts short-term (no longer than 30-days) visits by foreign regulatory counterparts and scientists who can come from as nearby as Canada, or as far away as Singapore. These visits may span from one hour to several days to several weeks in length.  Similarly, long-term visits (longer than 30 days) of researchers and scientists as fellows under several different programs routinely take place. These visits require background checks by FDA Security and can take as long as 6-months to obtain FDA clearance.

Related External Links

International Pharmacovigilance Cluster
	General prinicples: EMA-FDA Parallel Scientific Advice

                                                                                  Content current as of:
      09/18/2018
              
              
Regulated Product(s)
		 BiologicsInternational Activities

          
                        Regulatory Harmonization and Convergence
          Foreign Regulators – Information and Training Resources
          Foreign Regulator Information Exchanges
          International Engagements to Respond to Covid-19 Pandemic
          Quick Guide to Web Resources
          Foreign Regulatory Seminar (Web-Based): CBERs Regulation of Biologics


                        WHO Engagements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop